Fontolizumab: Difference between revisions
Appearance
Content deleted Content added
Script assisted update of identifiers for the Chem/Drugbox validation project (updated: 'CAS_number'). |
m Open access bot: doi updated in citation with #oabot. |
||
(15 intermediate revisions by 12 users not shown) | |||
Line 1: | Line 1: | ||
{{Short description|Monoclonal antibody}} |
|||
{{Drugbox |
{{Drugbox |
||
| Verifiedfields = changed |
| Verifiedfields = changed |
||
| Watchedfields = changed |
|||
| verifiedrevid = |
| verifiedrevid = |
||
<!--Monoclonal antibody data--> |
<!--Monoclonal antibody data--> |
||
| type = mab |
| type = mab |
||
| mab_type = mab |
| mab_type = mab |
||
| source = zu/o |
| source = zu/o |
||
| target = [[interferon gamma]] |
| target = [[interferon gamma]] |
||
⚫ | |||
⚫ | |||
| tradename = |
| tradename = |
||
| pregnancy_AU = |
| pregnancy_AU = |
||
Line 20: | Line 20: | ||
| legal_status = |
| legal_status = |
||
| routes_of_administration = |
| routes_of_administration = |
||
⚫ | |||
⚫ | |||
| bioavailability = |
| bioavailability = |
||
| protein_bound = |
| protein_bound = |
||
Line 27: | Line 26: | ||
| elimination_half-life = |
| elimination_half-life = |
||
| excretion = |
| excretion = |
||
⚫ | |||
⚫ | |||
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}} |
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}} |
||
| ChemSpiderID = |
| ChemSpiderID = |
||
| CAS_number_Ref = {{cascite| |
| CAS_number_Ref = {{cascite||??}} |
||
| CAS_number = |
| CAS_number = 326859-36-3 |
||
| ATC_prefix = none |
| ATC_prefix = none |
||
| ATC_suffix = |
| ATC_suffix = |
||
Line 42: | Line 40: | ||
| KEGG_Ref = {{keggcite|correct|kegg}} |
| KEGG_Ref = {{keggcite|correct|kegg}} |
||
| KEGG = D04242 |
| KEGG = D04242 |
||
⚫ | |||
⚫ | |||
| chemical_formula = |
| chemical_formula = |
||
⚫ | |||
⚫ | |||
}} |
}} |
||
'''Fontolizumab''' (planned trade name '''HuZAF''') is a [[ |
'''Fontolizumab''' (planned trade name '''HuZAF''') is a [[ monoclonal antibody]]<ref>[http://www.ama-assn.org/ama1/pub/upload/mm/365/fontolizumab.doc Statement On A Nonproprietary Name Adopted By The Usan Council - Fontolizumab], ''American Medical Association''.</ref> and an [[immunosuppressive drug]] for the treatment of [[auto-immune disease]]s like [[Crohn's disease]].<ref>{{cite journal|=ReinischW VilliersWBeneLSimonLRáczIKatzSAltorjayIFeaganBRiff|=|title=Fontolizumab in moderate to severe Crohn's disease: phase 2, randomized, double-blind, placebo-controlled, multiple-dose study|doi=10.1002/ibd.21038|= |=}}</ref> A phase II [[clinical trial]] investigating the use for [[rheumatoid arthritis]] was terminated because the first phase did not meet the [[clinical endpoint|endpoint]].<ref>{{ClinicalTrialsGov|NCT00281294|A Phase 2 Study to Evaluate the Safety, Tolerability, and Activity of Fontolizumab in Subjects With Active Rheumatoid Arthritis}}</ref> |
||
== References == |
== References == |
||
{{reflist}} |
|||
<references/> |
|||
{{Immunosuppressants}} |
|||
{{immunosuppressants}} |
|||
{{Monoclonals for immune system}} |
{{Monoclonals for immune system}} |
||
{{Cytokine receptor modulators}} |
|||
[[Category:Monoclonal antibodies]] |
|||
[[Category:Abandoned drugs]] |
|||
{{monoclonal-antibody-stub}} |
{{monoclonal-antibody-stub}} |
||
{{antineoplastic-drug-stub}} |
{{antineoplastic-drug-stub}} |
||
[[it:Fontolizumab]] |